Related Experiment Video

Updated: Sep 5, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine

Shang Mengxuan1, Zhou Fen1, Jin Runming1

  • 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in Pediatrics
|July 11, 2022
PubMed

Insights

Relapsed or refractory pediatric B-cell acute lymphoblastic leukemia (R/R B-ALL) is a major cause of death. Novel therapies, including immunotherapies and targeted drugs, are improving outcomes for these young patients.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Therapeutics

Background:

  • Relapse and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in children is a leading cause of cancer-related death.
  • Current multidrug chemotherapy has limitations in treating R/R B-ALL effectively.

Purpose of the Study:

  • To review recent advancements in therapeutic strategies for pediatric R/R B-ALL.
  • To highlight emerging technologies and novel drugs for individualized treatment approaches.

Main Methods:

  • Review of current literature on R/R B-ALL treatment strategies.
  • Analysis of new molecular targets, immunotherapies, and targeted drugs.
  • Discussion of prognostic indicators and genotypic changes in R/R ALL.

Main Results:

  • Significant progress has been made in improving the prognosis of pediatric R/R B-ALL patients.
  • Novel drugs and immunotherapies demonstrate increased efficacy and reduced toxicity.
  • These advancements aim to achieve minimal residual disease negativity and facilitate hematopoietic stem cell transplantation.

Conclusions:

  • Emerging technologies and innovative therapies are transforming the treatment landscape for pediatric R/R B-ALL.
  • Individualized treatment strategies based on molecular targets show promise.
  • The development of novel drugs has markedly enhanced the prognosis for pediatric patients with R/R B-ALL.

Keywords:
immunotherapypediatricspersonalized therapyrelapsed or refractory acute lymphoblastic leukemia (R/R ALL)targeted therapy

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
489